236 related articles for article (PubMed ID: 8948025)
21. Kinetic analysis of megakaryopoiesis induced by recombinant human interleukin 11 in myelosuppressed mice.
Saitoh M; Taguchi K; Momose K; Suga K; Ogawa Y; Yasuda S; Miyata K
Cytokine; 2001 Mar; 13(5):287-94. PubMed ID: 11243707
[TBL] [Abstract][Full Text] [Related]
22. Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice.
Shibuya K; Kuwaki T; Akahori H; Kato T; Miyazaki H
Leuk Res; 2004 Sep; 28(9):941-6. PubMed ID: 15234571
[TBL] [Abstract][Full Text] [Related]
23. Effect of PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on growth and differentiation of the HEL cell line.
Catani L; Gugliotta L; Motta M; Tazzari P; Baravelli S; Tura S
Haematologica; 1998 May; 83(5):385-91. PubMed ID: 9658720
[TBL] [Abstract][Full Text] [Related]
24. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation.
Molineux G; Hartley CA; McElroy P; McCrea C; McNiece IK
Blood; 1996 Aug; 88(4):1509-14. PubMed ID: 8695873
[TBL] [Abstract][Full Text] [Related]
25. Overview of the safety and biologic effects of PEG-rHuMGDF in clinical trials.
Sheridan W; Menchaca D
Stem Cells; 1998; 16 Suppl 2():193-8. PubMed ID: 11012191
[TBL] [Abstract][Full Text] [Related]
26. A highly enhanced thrombopoietic activity by monomethoxy polyethylene glycol-modified recombinant human interleukin-6.
Inoue H; Kadoya T; Kabaya K; Tachibana K; Nishi N; Sato M; Ohsawa M; Mikayama T; Mori KJ
J Lab Clin Med; 1994 Oct; 124(4):529-36. PubMed ID: 7930877
[TBL] [Abstract][Full Text] [Related]
27. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
[TBL] [Abstract][Full Text] [Related]
28. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
Fanucchi M; Glaspy J; Crawford J; Garst J; Figlin R; Sheridan W; Menchaca D; Tomita D; Ozer H; Harker L
N Engl J Med; 1997 Feb; 336(6):404-9. PubMed ID: 9010146
[TBL] [Abstract][Full Text] [Related]
29. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia.
Farese AM; Hunt P; Grab LB; MacVittie TJ
J Clin Invest; 1996 May; 97(9):2145-51. PubMed ID: 8621805
[TBL] [Abstract][Full Text] [Related]
30. Update on thrombopoietin in preclinical and clinical trials.
Miyazaki H
Curr Opin Hematol; 1998 May; 5(3):197-202. PubMed ID: 9664160
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells.
Neelis KJ; Dubbelman YD; Qingliang L; Thomas GR; Eaton DL; Wagemaker G
Exp Hematol; 1997 Sep; 25(10):1084-93. PubMed ID: 9293906
[TBL] [Abstract][Full Text] [Related]
32. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Grigg AP; Zalcberg J; Cohen B; O'Byrne J; Menchaca DM; Fox RM; Begley CG
Blood; 1997 May; 89(9):3118-28. PubMed ID: 9129014
[TBL] [Abstract][Full Text] [Related]
33. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
[TBL] [Abstract][Full Text] [Related]
34. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
[TBL] [Abstract][Full Text] [Related]
35. A mild transient decrease of peripheral red blood cell counts induced by a suprapharmacological dose of pegylated human megakaryocyte growth and development factor in rats.
Harada K; Ide Y; Tazunoki Y; Imai A; Yanagida M; Kikuchi Y; Imai A; Ishii H; Kawahara J; Izumi H; Kusaka M; Tokiwa T
J Pharm Pharmacol; 1999 Jul; 51(7):841-6. PubMed ID: 10467960
[TBL] [Abstract][Full Text] [Related]
36. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
Bennett CL; Evens AM; Andritsos LA; Balasubramanian L; Mai M; Fisher MJ; Kuzel TM; Angelotta C; McKoy JM; Vose JM; Bierman PJ; Kuter DJ; Trifilio SM; Devine SM; Tallman MS
Br J Haematol; 2006 Dec; 135(5):642-50. PubMed ID: 17054431
[TBL] [Abstract][Full Text] [Related]
37. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.
Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y
Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031
[TBL] [Abstract][Full Text] [Related]
38. Treatment of the Kasabach-Merritt syndrome with pegylated recombinant human megakaryocyte growth and development factor in mice: elevated platelet counts, prolonged survival, and tumor growth inhibition.
Verheul HM; Panigrahy D; Flynn E; Pinedo HM; D'Amato RJ
Pediatr Res; 1999 Nov; 46(5):562-5. PubMed ID: 10541319
[TBL] [Abstract][Full Text] [Related]
39. Megakaryocyte progenitors derived from bone marrow or G-CSF-mobilized peripheral blood CD34 cells show a distinct phenotype and responsiveness to interleukin-3 (IL-3) and PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF).
Catani L; Gugliotta L; Campanini E; Mangianti S; Gibellini D; Baravelli S; Vianelli N; Lemoli RM; Tura S
Br J Haematol; 1998 Jan; 100(1):207-18. PubMed ID: 9450813
[TBL] [Abstract][Full Text] [Related]
40. Marked improvement of thrombocytopenia in a murine model of idiopathic thrombocytopenic purpura by pegylated recombinant human megakaryocyte growth and development factor.
Shibuya K; Kuwaki T; Tahara E; Yuki C; Akahori H; Kato T; Miyazaki H
Exp Hematol; 2002 Oct; 30(10):1185-92. PubMed ID: 12384150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]